<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419042</url>
  </required_header>
  <id_info>
    <org_study_id>GFPC 05-05</org_study_id>
    <nct_id>NCT00419042</nct_id>
  </id_info>
  <brief_title>Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francais De Pneumo-Cancerologie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is in non small-cell lung cancer stage IV et IIIB (T4 with pleural
      effusion) in elderly dependent patients with evaluation of the sequence Gemcitabine first
      line followed by Erlotinib when progression versus Erlotinib first line followed by
      Gemcitabine when progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter phase II trial,prospective,randomized,open,non comparative
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TARCEVA</intervention_name>
    <description>Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.</description>
    <other_name>Erlotinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemzar</intervention_name>
    <description>GEMZAR by mixing it into a solution and giving it through a needle into a vein—called intravenous infusion (IV). This will take about 30 minutes</description>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non small-cell lung cancer stage IV et IIIB (T4 with pleural effusion) in
        elderly dependent patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 65

          -  Comorbidities score, PS and frailty score according to table 1

          -  No dementia, faecal or urinary incontinence, repeated falls

          -  ADL = 0, IADL = 0-1

          -  Life expectancy at least 12 weeks

          -  Creatinin clearance &gt; = 30 ml/mn (according to Cockcrofts-Gault formula)

          -  Competency to give written informed consent

          -  Haematological functions as follows : neutrophiles count &gt; 1.5 x 109/l and platelets &gt;
             100 x 109/l hemoglobin &gt; 9,5 g/dl - Hepatic function as follows : Bilirubin &lt; 1,25 LNS
             ASAT / ALAT &lt;5 x NAlcPh &lt;5 x N

          -  PS &lt; 3

          -  cerebral metastasis eligible if asymptomatic

          -  Histologically or cytologically confirmed NSCLC

          -  Stage IV/IIIB4 (T4 with pleural effusion)

          -  No prior chemotherapy

          -  relapses of previous NSCLC treated by surgery or radiotherapy are eligible, if the
             target is measurable out of initial radiotherapy field and if cytological or
             histological proof

          -  At least one measurable target lesion by RECIST guidelines

        Exclusion Criteria:

          -  symptomatic cerebral metastasis

          -  Any severe comorbidity calculated by Charlson score according to table 1

          -  ADL &gt; 0 and IADL &gt; 1- performance status &gt;2 (ECOG)

          -  peripheral neuropathy grade 2 or more

          -  dementia, repeated falls, urinary or faecal incontinence

          -  contra-indication to corticosteroids

          -  contra indication to a product of this study

          -  unwilling or unable to comply with study requirements, for personal, family,
             sociologic, geographic or any other reason

          -  inability of the subject to give written informed consent

          -  lack of liberty following legal or administrative decision

          -  hypersensitivity to polysorbate

          -  hypersensitivity to erlotinib or any excipients of this product

          -  unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of
             malabsorption in glucose or galactose

          -  participation in concomitant clinical trial

          -  bronchioloalveolar or neuroendocrine or composite carcinoma

          -  superior vena cava syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé LECAER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francais De Pneumo-Cancerologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Bastia</city>
        <zip>20200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Charleville Mezieres</city>
        <zip>08000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Elbeuf</city>
        <zip>76503</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>GAP</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 00</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Martigues</city>
        <zip>13695</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Meaux</city>
        <zip>77108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Rouen</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Villefranche Sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.g-f-p-c.org</url>
    <description>Groupement Francais de Pneumo-cancérologie</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>September 29, 2013</last_update_submitted>
  <last_update_submitted_qc>September 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>None small-cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

